We report that the earliest and thus clinically most promising mutations in osteosarcoma affect the cell cycle G1 transition, which is guarded by cyclins D3, E1, and cyclin‐dependent kinases 2, 4, and 6. The gene discussed is CCND3; the disease is osteosarcoma.